| 研究課題/領域番号 |
22KF0036
|
|---|
| 補助金の研究課題番号 |
22F32102 (2022)
|
|---|
| 研究種目 |
特別研究員奨励費
|
| 配分区分 | 基金 (2023)
補助金 (2022) |
|---|
| 応募区分 | 外国 |
|---|
| 審査区分 |
小区分47010:薬系化学および創薬科学関連
|
|---|
| 研究機関 | 東北大学 |
|---|
研究代表者 |
笠井 均 東北大学, 多元物質科学研究所, 教授 (30312680)
|
|---|
| 研究分担者 |
KUMAR SANJAY 東北大学, 多元物質科学研究所, 外国人特別研究員
|
|---|
| 研究期間 (年度) |
2023-03-08 – 2024-03-31
|
| 研究課題ステータス |
完了 (2023年度)
|
| 配分額 *注記 |
2,300千円 (直接経費: 2,300千円)
2023年度: 1,100千円 (直接経費: 1,100千円)
2022年度: 1,200千円 (直接経費: 1,200千円)
|
|---|
| キーワード | SN-38 / Homodimer / Disulfide linker / Prodrug / Fabrication / Nanoparticles |
|---|
| 研究開始時の研究の概要 |
SN-38, an active metabolite of well-known anticancer agent irinotecan. However, SN-38 cannot use as such as anticancer drug because of some limitation such as extreme water insolubility of SN-38 and the instability of the active lactone ring, therefor lack of pharmaceutically acceptable excipients. The purpose of this research is to develop new SN-38 related anticancer agent by substituent modification on SN-38 dimer, followed by develop stable nano-prodrug, which is having high drug loading capacity, highspecificity towards cancerous cells.
|
| 研究実績の概要 |
SN-38 homodimers (9 compounds) and SN-38-indoximod conjugates (with and without disulphide bond) were synthesized in highly efficient yield, followed by fabricated as nano-prodrugs by reprecipitation method. The fabricated nano-prodrug of SN-38 homodimers and SN-38-indoximod conjugate having disulphide bond with 0% and 10% PS80, respectively, were not aggregated in one week stored at 4 °C due disulphide bond may favour the nanoparticle preparation and dispersion stability. Whereas nano-prodrugs of SN-38-indoximod conjugate without disulphide bond with 0/1/10/100% PS80 were aggregated after fabrication. 80-160 nm sized nanoparticles were observed in fabricated nano-prodrugs of SN-38 homodimers and SN-38-indoximod conjugate having disulphide bond (with 10% PS80) in SEM image.
One SN-38 homodimer showed promising in vitro anticancer activity against cancer cells. This result was supported by drug release study under GSH condition in which >85% of SN38 was released from prodrug in 6 h in the presence of GHS. Whereas prodrug SN-38-indoximod conjugate without disulphide didn’t release SN38 under GSH environment due to absence of disulphide bond containing linker. Therefore, it didn’t show in vitro anti-cancer activity against either A549 cells or MCF7 cells.
|
